Technologies
PDF


WARF: P03289US

Antiviral Peptides and Methods for Inducing Cellular Resistance to Infection


INVENTORS -

Curtis Brandt, Hermann Bultmann

The Wisconsin Alumni Research Foundation is seeking commercial partners interested in developing peptides that are active against a broad spectrum of viruses.
OVERVIEWInfluenza virus causes millions of infections each year worldwide. Human parainfluenza virus (PIV) types 1,2,3 and respiratory syncytial virus (RSV) types A and B are the major viral pathogens responsible for causing severe respiratory tract infections in infants and young children. Approximately 4,000 children less than one year of age die each year in the United States from complications resulting from severe respiratory disease caused by infection with RSV and PIV-3.

No currently available product can effectively prevent infections from many respiratory viruses such as RSV or PIV. An antiviral peptide that can be easily and effectively administered to prevent infection from common respiratory viruses is needed.
THE INVENTIONUW–Madison researchers have developed peptides that are active against a broad spectrum of viruses. These peptides may be useful as prophylactic or therapeutic agents to treat multiple viral respiratory tract infections, eliminating the need for specific vaccines.

The peptides do not need to enter cells to inhibit viral infection. Instead, the peptides permanently inactivate virions in solution and can block viral infection at post-attachment steps such as during cell entry. Additionally, when cells in culture are treated with the peptides, the cells become resistant to infection for up to several hours. The cellular resistance is reinducible, and the treated cells become resistant within five minutes of exposure to the peptides.

Animal studies have confirmed that the peptides are active against influenza virus and protect from death even when administered 24 hours post-infection. Preliminary toxicity data show the peptides are not toxic to cells in culture at concentrations up to 150-200 micromolar. They are also not toxic in vivo at doses one thousand times higher than the IC50 values.
APPLICATIONS
  • Prophylactic and therapeutic agents to treat respiratory tract infections caused by multiple viruses
KEY BENEFITS
  • Effective against all enveloped viruses tested thus far, including HIV, HSV and several strains of influenza, including H1 and H5
  • Active at low micromolar concentrations
  • Inhibit viral infection through three mechanisms of action, including a novel mechanism involving the viral envelope
  • Easily administered – can be given via a nasal spray or as an inhaled powder
  • Show low toxicity both in vitro and in vivo
ADDITIONAL INFORMATION
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.